CLAIMS:

1. A composition comprising a nucleic acid polyplex comprising a cationic polymer and/or lipid, a therapeutic nucleic acid construct encoding interleukin-12 (IL-12), and a therapeutic nucleic acid construct comprising a nucleic acid encoding at least one RIG-I agonist, wherein the therapeutic nucleic acid constructs encoding IL-12 and RIG-I are the same or different nucleic acid constructs.

2. The composition according to Claim 1, wherein said RIG-I agonist is selected from the group consisting of eRNA11a, VA RNA1, eRNA41H, MK4621, SLR10, SLR14, and SLR20, and more preferably selected from the group consisting of eRNA41H, eRNA11a.

3. The composition according to Claim 1, wherein said cationic polymer is selected from the group consisting of polyethyleneimine (PEI), PAMAM, polylysine (PLL), polyarginine, chitosan, and derivatives thereof.

4. The composition according to Claim 3, wherein the cationic polymer comprises a derivatized chitosan, preferably an amino-functionalized chitosan.

5. The composition according to Claim 4, wherein said amino-functionalized chitosan comprises arginine and further comprises, or is functionalized with, a hydrophilic polyol, *e.g.* gluconic acid or glucose.

6. The composition according to any one of Claims 3-5, wherein the nucleic acid polyplex further comprises a reversible coating comprising one or more polyanion-containing block co-polymers having at least one polyanionic anchor region and at least one hydrophilic tail region, preferably wherein the polyanion-containing block co-polymer is a linear diblock and/or triblock co-polymer.

7. The composition according to Claim 1, wherein said therapeutic nucleic acid construct is comprised within a plasmid selected from the group consisting of: gWIZ, pVAX, NTC8685 or NTC9385R, optionally wherein said therapeutic nucleic acid construct further comprises an expression control element selected from the group consisting of CMV, EFla, CMV/EFla, CAG, and CMV/EFla/HTLV promoters.

8. The composition according to Claim 1, wherein said therapeutic nucleic acid construct further comprises a synthetic Beta-globin-based intron, optionally wherein said therapeutic nucleic acid construct further comprises a HTLV-IR.

9. The composition according to Claim 1, wherein said therapeutic nucleic acid construct further comprises kanamycin selection or sucrose-based selection element, optionally wherein said therapeutic nucleic acid construct further comprises a pUC or R6K origin of replication.

10. The composition according to any one of Claims 1-9, wherein said therapeutic nucleic acid construct encoding IL-12 comprises SEQ ID NO: 7.

11. Use of a composition according to any one of Claims 1-10 in the manufacture of a medicament for the localized expression of IL-12 in a mucosal tissue in a patient in need thereof.

12. Use of a composition according to any one of Claims 1-10 in the manufacture of a medicament for inhibiting the growth of a mucosal cancer cell in a patient in need thereof.

13. Use of a composition according to any one of Claims 1-10 in the manufacture of a medicament for treating bladder cancer in a patient in need thereof.

14. The use according to any one of Claims 11-13, further comprising that an additional immunostimulatory molecule selected from the group consisting of IFN-1 activators and immune checkpoint inhibitors is to be administered simultaneously or sequentially.

15. The use according to Claim 14, wherein said IFN-1 agonist and/or said immune checkpoint inhibitor is to be administered separately.

16. The use according to Claim 14 or 15, wherein said immune checkpoint inhibitor is selected from the group consisting of ipilimumab, tremelimumab, nivolumab, atezolizumab and/or pembrolizumab.